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Background: Adoptive transfer of minor histocompatibility antigen (MiHA)-specific T cells is a promising therapy for
patients with hematological cancers. However, the efficacy of the transferred cells is hampered by the acquisition of
terminal effector differentiation and exhaustion features during expansion in vitro thus preventing their function
and persistence in vivo. Yet, the factors that induce T-cell differentiation and functional impairment in culture remain
poorly defined and are likely to vary depending on the method used for expansion.
Methods: Using the clinically relevant HLA-A0201-restricted MiHA HA-1 as well as reagents and procedures that are
readily transferable to a clinical environment, we designed a novel culture protocol and defined how exhaustion
features appeared in function of time. The optimal time points for the expansion of “fit” MiHA-specific T cells were
delineated using phenotypic and functional assessments including KLRG-1 and PD-1 surface markers as well as Ki67
staining and cytokine secretion assays.
Results: Following a priming phase, an enrichment step and a rapid expansion stage, our method generates
MiHA-specific T-cell lines. Evidence of phenotypic and functional dysfunction appear in function of culture duration,
but display different characteristics following the extension of the priming or rapid expansion phases. While repeated
antigen exposure during the priming phase induced the decline of the antigen-specific population and the expression
of PD-1 and KLRG-1 on antigen-specific CD8+ T cells, the prolongation of an antigen-free expansion phase induced
proliferation arrest and the relative loss of antigen-specific cells without impairing polyfunctional cytokine secretion
or inducing PD-1 and KLRG-1 expression. A similar pattern was also observed after stimulating a virus-specific
memory repertoire, except for the more rapid acquisition of exhaustion features upon repeated antigen exposure.
Conclusion: Our results offer novel insights on the impact of culture duration on the acquisition of T-cell exhaustion
features. Using a new clinical-compliant protocol, we define critical parameters to monitor in order to optimally
differentiate and expand MiHA-specific T cells in culture prior to adoptive transfer.
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Allogenic hematopoietic stem cell transplantation (HSCT)
can cure hematological malignancies refractory to cyto-
toxic therapy. The therapeutic potential of HSCT largely
depends on the so-called graft-versus-leukemia (GVL) ef-
fect mediated by donor T cells recognizing alloantigens on
the malignant cells [1-3]. In most cases, HSCT donors and
recipients are fully matched at Human leukocyte antigen
(HLA) loci, making Minor histocompatibility antigens
(MiHA) the main targets of the GVL effect. MiHAs are
naturally processed peptides from polymorphic endogen-
ous proteins that are loaded onto HLA molecules and pre-
sented at the cell surface [4]. At this time, MiHA-based
immunotherapy in the setting of HSCT is one of the most
potent forms of cancer treatment, but it remains non-
specific and can lead to widespread anti-host alloreactivity
in the form of Graft-versus-host disease (GVHD) [5].
Hence, the differentiation, expansion, and adoptive trans-
fer of hematopoietic-restricted MiHA-specific T cells is an
attractive approach to augment the GVL effects without
risking GVHD [6,7].
The adoptive transfer of MiHA-specific CD8+ T-cell
clones and lines in humans has yielded mixed results
[1,8]. Globally, some objective leukemia responses were
seen, but no long-term evidence of leukemia control or
cure were recorded. A likely explanation for the limited
success of these pioneering studies was the lack of per-
sistence of the T cells after transfer. Large scale ex vivo
T-cell expansion and effector differentiation can lead to
robust antigen-specific cytolysis in vitro, but also to ter-
minal effector differentiation and poor capacity to fur-
ther expand and persist in vivo. Accumulating evidence
from both animal and human studies suggest that optimal
therapeutic effects are achieved when the ex vivo gener-
ated T cells maintain features associated with early mem-
ory differentiation [9,10]. Hence, a compromise must be
sought to ensure efficient antigen priming while limiting
effector differentiation during the culture period.
We developed a clinical-compliant protocol based on
procedures and reagents that have been used in clinical tri-
als before or that are manufactured clinical grade to prime
and expand T-cell lines against HA-1, a HLA-A0201-
associated, immunodominant and hematopoietic-specific
MiHA [11,12]. Our approach is based on a priming phase
in gas-permeable culture vessels (G-Rex), where responder
cells are cocultured with antigen-loaded dendritic cells,
followed by an enrichment step and a rapid expansion
protocol (REP). We aimed at identifying the optimal
time points to obtain T-cell lines comprising func-
tional and non-exhausted MiHA-responsive T cells.
To this end, we evaluated the effects of culture dur-
ation at each step by assessing the expression of ter-
minal differentiation markers and evaluating T-cell
functionality. Our data support that phenotypic andfunctional exhaustion features were different according to
culture stage (priming versus expansion) implying that the
evaluation of T-cell fitness for immunotherapy must rely
on several parameters that are greatly influenced by the
type and duration of culture method. Hence, we propose a
novel clinical-compliant protocol to generate and expand




Healthy volunteers expressing the HLA-A0201 allele had
their HA-1 genotype determined by SBTexcellerator kit
(GenDX, Utrecht, The Netherlands) and were selected
on the basis of the HA-1RR genotype (not endogenously
expressing HA-1)[12]. Peripheral blood mononuclear
cells (PBMCs) were obtained by venipuncture or apher-
esis followed by manual (Ficoll-Paque, GE Healthcare,
Baie d’Urfe, QC) or automated (Sepax system, Biosafe
America Inc., Houston, TX) gradient density separation.
This study was approved by the local Research Ethics
Committee. Epstein-Barr virus serological status was deter-
mined by detection of anti-Viral capsid antigen (VCA) IgG
and Epstein-Barr nuclear antigen (EBNA) by immunofluor-
escence in our local clinical diagnostic laboratory.
Dendritic cell (DC) generation
Monocytes from PBMCs were isolated by plastic adher-
ence and cultured in DC medium (X-vivo 15, 5% human
serum, 1X PSG, 1 mM sodium pyruvate) supplemented
with 800 IU/mL GM-CSF (Feldan, Quebec, QC) and
1000 IU/mL IL-4 (Feldan). Dendritic cells were matured
with GM-CSF, IL-4, TNFα (10 ng/mL), IL-1β (10 ng/
mL), IL-6 (100 ng/mL) (Feldan) and prostaglandin E2
(1 μg/mL) (Sigma-Aldrich, Oakville, ON).
T-cell line generation
Antigen-specific T cell lines were generated using 15 × 106
PBMCs as responder cells and cocultured with autolo-
gous, peptide-loaded mature DCs as antigen presenting
cells (APCs) at a 1:10 ratio (stimulator:effector). After
40 Gy irradiation, the DCs were loaded with 1 μg/mL
HA-1 (VLHDDLLEA) (Genscript, Piscataway, NJ) or
LMP2426-434 (CLGGLLTMV) (Anaspec, Fremont, CA).
Cells were cocultured for 7 days in T-cell medium (Ad-
vanced RPMI 1640, 10% human serum, 1X L-glutamine)
supplemented with IL-21 (30 ng/mL) and IL-12 (10 ng/
mL) (Feldan) in a G-Rex10 vessel (Wilson Wolf Manufac-
turing, New Brighton, MN). At day 7, T cells were
washed and restimulated with peptide-pulsed DCs and
incubated in T-cell medium supplemented with IL-21,
IL-2 (100 IU/mL), IL-7 (10 ng/mL) and IL-15 (5 ng/mL)
(Feldan) for an additional week. Restimulations of T cells
were performed weekly on day 14 and day 21 (up to 4
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IL-7 and IL-15. Cytokines were replenished with half
medium change at day 10, 18 and 25. The cell concentra-
tion was adjusted to 0.5 × 106 cells/mL each week.
After 21 days, IFNγ-secreting cells from G-Rex culture
were selected with the IFNγ Secretion Assay - Detection
Kit (Miltenyi Biotec, San Diego, CA) according to the
manufacturer’s instructions. Briefly, T cells were stimu-
lated for 4 hours with appropriate antigenic peptide, la-
beled with an IFNγ catch reagent and an IFNγ detection
antibody conjugated to R-phycoerythrin (PE) and magnet-
ically harvested using anti-PE MicroBeads and a MACS
separator (Miltenyi Biotec).
Selected IFNγ-secreting T cells were expanded in vitro
using an adaptation of a previously described rapid ex-
pansion protocol (REP) [13]. Following IFNγ capture,
approximately 5 × 104 T cells were resuspended in
25 mL of T-cell medium containing 25 x 106 irradiated
(40 Gy) autologous PBMCs, 30 ng/mL OKT3 and 50 IU/
mL IL-2 and transferred to a T25 tissue culture flask for
21 days. After 4 days, cultures were harvested and resus-
pended in 25 mL of fresh T-cell medium with 50 IU/mL
IL-2. Half medium changes were performed every 3-4
days until the end of the culture. Cells were harvested at
day 12 and 21 of the REP culture for analysis.
IFNγ enzyme-linked immunospot assay (ELISpot)
ELISpot assays were used according to the manufac-
turer’s instructions (Mabtech Inc., Cincinnati, OH) with
1 × 105 cells. Corresponding spot forming cells and ac-
tivity per 1 × 105 cells were determined on a vSpot
Reader Spectrum (AID, Strassberg, Germany).
Flow cytometry
Immunophenotyping
The phenotype of T cells was assessed at different time
points of the culture by flow cytometry. To determine
the antigenic specificity, HLA-A0201/HA-1 dextramer
(Immudex, Copenhagen, Denmark) or HLA-A0201/LMP2
pentamer (ProImmune, Sarasota, FL) staining was per-
formed. 7-AAD was used to attest for viability. Cells
were surface stained with monoclonal antibodies to:
CD3, CD4, CD8, CD45RO, CCR7, CD11c, CD19,
CD56, CD14 (BD Biosciences, Mississauga, ON),
CD62L, PD-1, CD57, KLRG-1 (BioLegend, San Diego,
CA) or CD8 (eBiosciences, San Diego, CA), washed
and fixed in PBS 2% FBS 1% PFA before acquisition on
a LSRII instrument (BD Biosciences, Mississauga,
ON). To determine the TCR repertoire diversity of
antigen-specific CD8+ T cells, the analysis of Vβ distri-
bution was performed using the IO Test Beta Mark
TCR Vβ Repertoire kit (Beckman Coulter, Mississauga,
ON) according to the manufacturer’s instructions on
HLA-A0201/HA-1 dextramer positive cells. All datawere subsequently analyzed using Flowlogic software
(Inivai Technologies, Mentone, Australia).
Intracellular staining
To evaluate T-cells function, cells were incubated with
5 μg/mL antigenic peptides in the presence of brefeldin
A (7.5 μg/mL) (Sigma-Aldrich), anti-human CD28/
CD49d as costimulatory reagents (1 μg/mL) (BD Biosci-
ences) for 4 hours. Subsequently, cells were stained for
surface markers, then fixed, and permeabilized for intra-
cellular staining using Foxp3 staining buffer set from
eBiosciences according to the manufacturer’s instruc-
tions. Permeabilized cells were then incubated with
IFNγ, IL-2, TNFα (BD Biosciences), Ki67 (BioLegend)
antibodies (BD Biosciences) and resuspended in PBS 2%
FBS 1% PFA before acquisition. For degranulation po-
tential, BD GolgiStop solution, anti-CD107a and anti-
granzyme B (BD Biosciences) were used. T cells treated
with phorbol 12-myristate 13-acetate (PMA; 50 ng/ml)
and ionomycin (500 ng/ml) (Sigma-Aldrich) were used as
positive controls. Acquisition was performed with a LSRII
flow cytometer and data were analyzed using Flowlogic
software.
Cytotoxicity assay
Specific cytotoxicity of T cells was measured in a standard
4 hour Cr51 release assay using autologous or allogenic
Phytohemaglutinnin (PHA, Sigma-Aldrich) blasts labeled
with Cr51 and loaded or not with antigenic peptides. The
percentage of specific lysis was calculated as followed: spe-
cific lysis = [(experimental release-spontaneous release)/
(maximum release-spontaneous release)] × 100 [14] at a
ratio of 40:1 (effector:target).
Statistical analysis
Statistical analyses were performed with IBM SPSS Sta-
tistics 21 software (Armonk, NY). A Shapiro-Wilk Test
of Normality showed that we could not always assume
normally distributed data. Thus, a one-tailed Wilcoxon
signed rank test was used for all comparisons. P values
of less than 0.05 were considered significant.
Results
Antigen-presenting cells efficiently prime MiHA-specific T
cells in G-Rex bioreactors
Based on established methods [1,8,15-17], we assessed the
effect of repetitive weekly stimulation on the priming and
expansion of MiHA-specific CD8+ T cells. We performed
HA-1-loaded autologous dendritic cell (DC) stimulations
of peripheral blood mononuclear cells (PBMCs) as a
source of responder HA-1-specific CD8+ T cells for four
different donors. This coculture was done in G-Rex biore-
actors, as used by others [18], to maximize cellular expan-
sion starting from only 15 million PBMCs. During this
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stages of the culture (IL-12 and IL-21 the first week;
IL-21, IL-2, IL-7 and IL-15 the second week and IL-2,
IL-7 and IL-15 for the subsequent weeks) to promote
T cell differentiation, survival and expansion [19-23].
We monitored this coculture for a total of four weeks.
According to our conditions, T-cell lines entered their
exponential growth phase around day 14 and reached
their maximal growth rate between days 21 and 28 to
achieve a total of ~25 to 140-fold expansion (Figure 1A).
In parallel, cocultures with unpulsed DCs were per-
formed as control and showed more modest expansions,
although the difference was not statistically significant.
Since total PBMCs were used as the source of responder
cells, we monitored for the presence of non-T cells and
the subset distribution amongst CD3+ cells. We observed
a balanced CD8/CD4 ratio (Additional file 1: Figure S1A).
More than 90% of cells were CD3+ at each analyzed
time points and we found that there was a negligible
amount of B cells or monocytes/macrophages and a
low but stable percentage of NK cells persisting over
time (~5%) (Additional file 1: Figure S1B).
The proportion of multimer-positive cells varied exten-
sively throughout the culture (Figure 1B and AdditionalFigure 1 Generation of MiHA-specific T-cell lines in coculture. (A) Kinetics of cultu
of PBMCs seeded at the beginning of the coculture step; n=4. (B) left: one repres
cytometry; middle: combination of 4 donors, data show average of donors ± SEM;file 2: Table S1) and displayed an oligoclonal Vβ chain ex-
pression pattern (Additional file 1: Figure S1C). The pres-
ence of HA-1 multimer-positive CD8+ T cells was found
in all cell lines by day 21 but tended to decrease during
the subsequent week (respective means of 2.1% to 0.36%).
This implies that a minimum of three DC stimulations are
needed to reliably achieve the generation of detectable
MiHA-specific T cells and that prolongation of culture
duration rapidly leads to a decline in the proportion of
antigen-specific T cells.
Longer coculture duration induces expression of markers
indicative of T-cell terminal differentiation
We then decided to compare cells harvested at 21 days
(three DC stimulations) and 28 days (four DC stimula-
tions). At both time point of the coculture phase, 30-40%
of HA-1-specific CD8+ T cells displayed expression of
CD45RO with CD62L and/or CCR7 (Figure 2A). This per-
centage did not change as a function of time suggesting
that this system preserved the central memory phenotype
typically associated with the early stages of T-cell differen-
tiation and, in the context of adoptive immunotherapy,
the capacity to further expand and persist in vivo [24].
Next, we characterized the differentiation status ofre growth as represented by the fold increase in cell count from the number
entative of the CD8+ HA-1+ cells generated over time analyzed by flow
right: variation of CD8+ HA-1+ over time for each donor. ns (non significant).
Figure 2 Induction of terminal differentiation marker expression in coculture over time. (A) CD45RO, CD62L and CCR7 expression on HA-1
multimer-positive cells. (B) left: representative plots and right: combination of PD-1 and KLRG-1 expression over time on HA-1+ and HA-1-
CD8+ T cells; n = 4. Comparison of (C) PD-1 and (D) KLRG-1 expression between the multimer-positive and negative CD8+ T-cell fractions
within the cultures at different time points ; n = 4, data represented as average ± SEM. *, P < 0.05.
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inhibitory receptors associated with T-cell dysfunction
[25,26]. In cocultures, the proportion of HA-1-specific
cells expressing PD-1 or KLRG-1 was higher at day 28
compared to day 21. The upregulation of these
markers over time was also consistent among individ-
ual cell lines (Figure 2B). Thus, our 21 day coculture
protocol enriched non-exhausted antigen-specific T
cells while pursuing at day 28, using a fourth DC
stimulation, increased PD-1 and KLRG-1 expression
in a multimer-positive CD8+ T cell-specific manner
(Figure 2C and D) hinting at the possibility that
coculture-specific factors drive phenotypic exhaustion.
Hence, our data suggest that time-dependent expres-
sion of terminal differentiation markers is distinctlyregulated depending on the number of antigen-
presenting cell stimulations.
Cytokine capture followed by a rapid expansion protocol
allows for enrichment of MiHA-specific CD8+ T cells
Knowing that four DC stimulations induced robust T-cell
expansion but a relative decline and phenotypic exhaus-
tion of antigen-specific cells, we focussed on day 21 cul-
tures as a source of “fit” MiHA-responsive cells (i.e.
optimal proportion of antigen-specific cells with low
expression of markers showing evidence of terminal differ-
entiation). In order to enrich for HA-1-specific cells, we
opted for an IFNγ capture procedure at day 21 of the co-
culture. This procedure has the non-negligible advantage
of having been used in clinical studies [27-30] and, as
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richment of IFNγ producing cells for different peptides or
peptide libraries for which multimers may not be available.
Following this step, cells were expanded with a rapid ex-
pansion protocol (REP) using anti-human CD3 antibody
(OKT3) and IL-2 [13]. In order to address the main ob-
jective of this study, we monitored this culture from 12 to
21 days to define the impact of culture duration on T-cell
phenotype and function.
In the REP culture, cells rapidly expanded (~76 to ~640-
fold) within the first 12 days and continued their growth
to reach a maximum of ~2000-fold expansion after 21 days
(Figure 3A). Similar to the initial coculture, the proportion
of HA-1-specific cells fell between 12 and 21 days in REP
in all cell lines (respective means of 8.36% to 1.64%)
(Figure 3B).
T-cell lines primed in vitro contain large numbers of
polyspecific T cells that are not specific for the targeted an-
tigen(s). Nonetheless, clinical studies have shown that T-
cell lines do not induce GVHD when injected into allogenic
recipients [8,31]. In the perspective of clinical translation,Figure 3 Expansion of MiHA-specific T-cell lines in REP. (A) Kinetics of cultu
number of IFNγ-secreting cells seeded at the beginning of the REP step; n
time analyzed by flow cytometry; right: variation of CD8+ HA-1+ over time for
assay of autologous or allogenic HLA-A0201 HA-1Neg cells pulsed or not withthe innocuity of the T-cell lines must be ascertained. We
confirmed that after 12 days of REP, the cell lines were not
cytotoxic to autologous or HLA-disparate, HA-1-negative
targets (all sharing the HLA-A0201 allele but mismatched
at 4 to 7/8 HLA loci) in the absence of the antigenic pep-
tide. However, HA-1-dependent cytolysis could be demon-
strated against both autologous and allogenic HLA-A0201
targets pulsed with peptide (Figure 3C). We also deter-
mined that T cells from the REP at day 21 remained cyto-
toxic when stimulated with HA-1 peptide but not with an
irrelevant HLA-A0201-associated peptide as evidenced by
CD107a and granzyme B co-expression (Additional file 3:
Figure S2).
Extending the REP induces proliferation inhibition
without altering polyfunctionality
Comparable to what we have seen in the coculture phase,
the proportion of HA-1 multimer-positive CD62L-
expressing cells remained stable during the REP phase, but
unexpectedly, the proportion of antigen-specific CD8+ T
cells expressing CCR7 consistently rose at day 21 of there growth as represented by the fold increase in cell count from the
= 4. (B) left: one representative of the CD8+ HA-1+ cells generated over
each donor. (C) Percentage of specific lysis measured with a Cr51 release
HA-1 peptide; n = 4. *, P < 0.05; **, P < 0.01.
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enrichment at day 21 of the coculture and further expan-
sion in the REP, the proportion of PD-1 and KLRG-1 posi-
tive cells remained low (Figure 4B). Hence, the IFNγ
capture procedure enriched non-exhausted antigen-specific
T cells, and the REP culture allowed for their expansion
without the induction of PD-1 or KLRG-1 expression.
We therefore sought to analyze, in more detail, the func-
tionality of CD8+ T cells at the different time points of the
REP culture. The IFNγ ELISpot assay provides a sensitive
estimation of antigen-specific T-cell responses. In accord-
ance with the frequency of HA-1 multimer-positive T cells
found both at 12 and 21 days, we determined that the REP
enhanced the proportion of IFNγ-secreting cells detected
after re-exposure to HA-1 when compared to pre-IFNγ
capture cocultures (Figure 4C). We further examined the
antigen-specific response during the REP by intracellular
flow cytometry to evaluate TNFα, IFNγ and IL-2 produc-
tion by CD8+ T cells after peptide exposure in vitro. In a
reproducible manner, the proportion of cytokine secreting
cells declined over time in the REP (Figure 4D). Again, this
correlated with the decreased percentage of multimer-
positive cells present within the culture. Conversely, the
proportion of polyfunctional T cells among the IFNγ-
producing fraction increased over time (Figure 4E), sug-
gesting that REP extension may favor the persistence or
expansion of polyfunctional over monofunctional cells.
However, the percentage of late REP CD8+ T cells (day 21)
expressing Ki67 decreased indicating that the proportion
of actively proliferating cells declined with time in REP
(Figure 4F). Nevertheless, as demonstrated by intracellular
staining following HA-1 peptide restimulation, the fall in
actively proliferating cells was not antigen-dependent
since HA-1-reactive IFNγ-secreting cells were similarly af-
fected when compared to non-reactive IFNγ-negative cells
(Figure 4G). Our results clearly indicate that REP duration
adversely impact the proportion of antigen-reactive cells
and globally blunts the proliferative response of antigen-
reactive and non-reactive T cells.
The kinetics of exhaustion vary depending on the nature
of the antigen
Since the development of exhaustion/dysfunction varies as
a function of time and expansion method (coculture vs
REP), it may also depend on the targeted antigen. We used
3 available donors from whom we had generated anti-HA-
1 T-cell lines to assess whether similar or divergent fea-
tures of the antigen-specific T cell phenotype would be
observed following priming and expansion against another
antigen. We selected a HLA-A0201-restricted peptide de-
rived from the Epstein-Barr virus (EBV) antigenic protein
LMP2. Viral antigens and MiHAs are both “foreign” pep-
tide sequences capable of eliciting strong T-cell responses.
A salient difference is that the 3 donors had all beenpreviously exposed to EBV (positive serology - not shown).
We could therefore evaluate whether our protocol would
have a different impact on the stimulation of a memory in-
stead of naïve repertoire in the same individuals. Following
three peptide stimulations, LMP2426-434-specific CD8
+ T
cells represented up to 10% of CD8+ T cells following a
total T-cell expansion comparable of that of HA-1 supple-
mented cultures (Additional file 4: Figure S3). However,
the proportion of multimer-positive T cells expressing
PD-1 or KLRG-1 was already high on day 21 of the co-
culture and remained stable on day 28 (Figure 5A). In
stark contrast with our observation with HA-1, there
was a substantial decline in the proportion of Ki67-
expressing CD8+ T cells from day 21 to day 28 of the
coculture (Figure 5B). This suggests that the acquisition
of exhaustion features occurred more rapidly in the
context of repeated exposure to the EBV-derived anti-
gen. Likewise, Ki67 staining sharply fell from REP day
12 to REP day 21 with little variations in the proportion
of antigen-specific CD8+ T cells expressing PD-1 or
KLRG-1 (Figure 5A and B). Nonetheless, as for anti-
HA-1 T-cell lines, antigen-specific cytokine secretion
tended to decline between day 12 and day 21 of the
REP in each independent sample tested (Figure 5C).
Altogether, these results suggest that the acquisition of
phenotypic and functional T-cell exhaustion features
vary according to the targeted antigen in the same do-
nors. This would imply that the timing of cell harvest-
ing for adoptive transfer might need to be fine-tuned
according to the targeted antigen.Discussion
In the context of HLA-identical hematopoietic cell trans-
plantation, the anti-MiHA alloresponse is the basis of the
GVL effect, one of the strongest forms of cancer immuno-
therapy. However, the adoptive transfer of ex vivo primed
and expanded MiHA-specific T-cell clones or lines have
failed to provide decisive anti-leukemia responses. With
the caveat that previous anti-MiHA adoptive immuno-
therapy clinical studies were done in advanced, hard to
treat leukemia patients, it is also possible that the ex vivo
generated MiHA-specific T cells used in these trials had
reached some level of exhaustion in vitro prior to adoptive
transfer. In recent years, a growing consensus has emerged
around the notion that the cytokine environment, re-
peated antigenic stimulations or culture duration used to
generate a high number of antigenic-specific T cells can
induce terminal T-cell effector differentiation and exhaus-
tion thereby limiting in vivo therapeutic efficacy [15]. De-
termining the optimal culture conditions to generate less
differentiated and non-exhausted T cells is thus highly
relevant for adoptive immunotherapy. Moreover, defining
the phenotypic or functional characteristics that reliably
Figure 4 Induction of functional exhaustion in REP over time. (A) Left: CD45RO, CD62L and CCR7 expression on HA-1 multimer-positive cells in
REP and right: increase of the percentage of CD8+ HA-1+ CCR7+ for each donor over time. (B) PD-1 and KLRG-1 expression over time on HA-1
multimer-specific CD8+ T cells; For A and B; n = 4, histograms represent means ± SEM. (C) Cells in each culture steps were harvested and stimulated
in vitro with HA-1 peptide. Specific IFNγ spot forming cells (SFC) were measured and compared to non-stimulated cells with the ELISpot assay; dotted
line represent detection threshold, n = 4, data show average ± SEM. (D) Cells from REP cultures were harvested over time and submitted to intracellular
staining for flow cytometry analysis of TNFα, IFNγ and IL-2 production after HA-1 peptide restimulation; left: representative plots and right: representation in
each culture. (E) Proportion of TNFα secretion in IFNγ-positive cells in every cell lines. (F) left: one representative and right: percentage of CD8+ Ki67+ for
each donor in the REP over time. (G) comparison of Ki67 expression between the IFNγ-positive and negative CD8+ T-cell fractions within the cultures after
HA-1 peptide restimulation. *, P< 0.05.
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Figure 5 Kinetics of phenotypic and functional exhaustion profile depending on the nature of the stimulating antigen. (A) CD8+ LMP2426-434
+ cells
expressing PD-1 and KLRG-1 in both culture steps over time; n = 3, data represented as average ± SEM. (B) CD8+ T cells at each culture time points
were analysed by flow cytometry for intracellular staining of Ki67; left: one representative and right: n = 3, data represented as average ±
SEM. (C) Intracellular staining analysis of TNFα, IFNγ and IL-2 production after LMP2426-434 peptide restimulation at day 12 and 21 of the
REP.
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culture or predict for in vivo efficacy is essential [32].
A paradigm shift is occurring in the field of adoptive
immunotherapy after it was found in several models that
therapeutic efficacy depended on the phenotype and the
“early” differentiation of antigen-specific T cells rather
than the number of cell infused. Hence a major focus of
this work was to evaluate the impact of culture duration
on T-cell differentiation and expansion. Based on these
results, we propose a new protocol for the optimal gen-
eration of non-exhausted MiHA-specific T-cell lines
(Figure 6). We have developed a strategy based on sev-
eral previously described approaches. Our system is
based on material and reagents that can be made clinicalgrade, and as such offers the advantage to be rapidly
adaptable to a clinical environment. Moreover, it was de-
signed to take advantage of a cytokine combination that
has been shown to promote priming and enhance sur-
vival of antigen-specific T cells [22,23,33,34]. IL-15 is
generally considered to be a regulator of T cell homeo-
stasis because it works with other common γ-chain cyto-
kines, like IL-2 and IL-7, to control the maintenance of
naive and memory T cell populations as well as to pro-
mote the survival of antigen-specific CD8+ T cells. These
latter cytokines were thus used from the second stimula-
tion until the end of the coculture [20,35-38]. Since IL-21
has been shown to prevent apoptosis and terminal differ-
entiation as well as further drive expansion of the cells
Figure 6 Proposed protocol for the priming, enrichment and rapid expansion of non-exhausted MiHA-stimulated T-cell lines. Schematic representation
of the protocol showing the coculture and the REP with the associated cytokines used in cultures.
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ation with IL-15 during the priming of antigen-specific
CD8+ T cells, it was introduced early in the beginning of
the coculture and kept for two weeks [19,39,40]. It may
also program effector cells to reacquire central memory
features after adoptive transfer and persist in vivo [19].
Finally, Il-12 was used only during the first week to take
advantage of its capacity to promote naïve CD8+ T cell
priming [41,42].
From only 15 million PBMCs as starting material, we
aimed at maximizing DC-T cell interactions and cell growth
while minimizing manipulations using a single gas-
permeable vessel [17]. In order to enrich multimer-positive
cells while limiting repeated stimulations, we decided to
proceed to antigen-specific cell enrichment at day 21 of our
coculture, which is comparable or shorter than previously
published methods [1,6,32]. The IFNγ capture procedure
for specific cells enrichment is amenable to several types of
antigens and has been used in the past to enrich MiHA-
specific cells [16]. This method is particularly useful when
other methods of cell separation or enrichment, such as
multimer-based sorting, cannot be done [43,27]. Enriched
MiHA-specific cell lines were further expanded for 12 days
according to an adaptation of a previously described REP
procedure [13]. This has already been proven to rapidly
and efficiently expand T cell clones or tumor-infiltrating
lymphocytes (TIL), and, in our case, rapidly expanded cell
lines enriched in HA-1-specific T cells [44,45].
Our protocol generates both central memory and ef-
fector memory phenotype T cells based on CCR7 and/orCD62L expression on CD45RO+ cells. According to previ-
ous studies, central memory T cells are predicted to have
increased in vivo efficacy relative to effector memory T
cells. However, there is also evidence that a fraction of ef-
fector memory T cells have the potential to revert back to
a central memory phenotype when transferred into patient
and persist, indicating that the acquisition of effector
memory phenotype in culture may not always predict lim-
ited functionality in vivo [19,46]. Nevertheless, the propor-
tion of effector memory or central memory phenotype
cells in both culture conditions (coculture and REP) did
not predict loss of antigen-specific cells or decline in their
functionality. Thus, it was imperative to find complemen-
tary features that would better characterize specific T cell
lines to attest their differentiation and functional status.
In the coculture step of our protocol, it is likely that re-
peated antigenic stimulation led to terminal differenti-
ation, as evidenced by upregulation of PD-1 and KLRG-1
predominantly on antigen-specific cells. This corroborates
previous results showing that repeated peptide-pulsed
DCs exposure can adversely affect antigen-specific T-cell
yield [15]. Thus, for the minor histocompatibility antigen
HA-1 in our system, three DC stimulations (for a total of
21 days of culture) offered the best generation of specific
T cells with a favorable differentiation status. This is fur-
ther supported by the fact that the REP, where no specific
antigen stimulation occurs, did not induce PD-1 and
KLRG-1 expression over time.
In the REP, the decrease in the proportion of cytokine-
producing cells was correlated with a loss of multimer-
Janelle et al. Journal of Translational Medicine  (2015) 13:123 Page 11 of 13positive cells. However, the antigen-reactive cells persist-
ing after 21 days of REP were polyfunctional, in greater
proportion than at day 12. This was rather surprising as
we expected that further IL-2 driven expansion would lead
to terminal differentiation and functional impairment [47].
Given that the proportion of antigen-specific cells express-
ing CCR7, a central memory marker, is also increased after
21 days of REP, one can speculate that early differentiated,
fit and polyfunctional T cells preferentially persisted in
culture as compared to other antigen-reactive cells. How-
ever, it is also possible that IL-21 addition during the
priming phase programmed the re-expression of memory
markers at later REP times [15,19]. Nonetheless, the pro-
portion of proliferating cells fell dramatically by 21 days in
REP, suggesting the possibility that cells had acquired a
certain degree of dysfunction. In the context where both
antigen-reactive and non-reactive CD8+ T cells lost their
proliferative response, one must consider that the relative
decline in antigen-reactive cells might be due to increased
apoptosis. Other studies have also reported that cell prolif-
eration could be inhibited without altering the cytokine
production of antigen-specific T cells [48]. In our REP pro-
cedure, cytokine production of MiHA-specific CD8+ T
cells proved to be modulated by mechanisms divergent
from proliferation as well. This could potentially be influ-
enced by the production of nitric oxide (NO) synthase by
autologous PBMCs within the culture which can have
inhibitory effect on T-cell division without necessarily af-
fecting cytokine secretion capacity [49,50]. Hence, in REP
procedure, unlike in some other contexts [25,26], exhaus-
tion appears to be independent of PD-1 and KLRG-1 ex-
pression or polyfunctionality but manifests itself by a
drastic decline in proliferation and persistence and should
therefore not last longer than 12 days. Thus, our protocol
shows that an improved balance composed of no more
than three DC stimulations followed by 12 days of
antigen-specific IFNγ-secreting T-cell expansion would
allow for the expansion of non-exhausted MiHA-specific
T cells.
It was somewhat surprising that similar culture condi-
tions led to different T-cell phenotypes when another anti-
gen was used. As previously shown, the stimulation of a
naïve repertoire requires more activation signals than the
stimulation of memory T cells [51,52]. To compare the
phenotype of in vitro generated MiHA-specific CD8+ T
cells under different conditions to another peptide, we
purposely chose an antigen that would stimulate a mem-
ory repertoire rather than a naïve repertoire in more than
90% of adults. LMP2426-434 –specific T cells, as opposed to
HA-1 specific T cells, more rapidly expanded but dis-
played exhaustion marker expression, perhaps as a conse-
quence of less stringent requirements for activation, a
lower dependency on costimulatory signals and a shorter
requirement of antigenic stimulation [53,54]. This mayalso be a matter of TCR affinity implying that a stronger
interaction lead to a more robust T-cell response [55]. The
functional avidity can also impact CD8+ T cell activation
since it is considered as a quantitative determinant of the
activation threshold of a T-cell clone [56,57]. Hence, dif-
ferentiation and expansion protocols used for stimulating
a memory repertoire might need to be optimized depend-
ing on affinity, avidity and progenitor frequency.
Conclusion
Altogether our results indicate that phenotypic and
functional exhaustion are greatly affected by duration
of the culture and display different characteristics ac-
cording to the culture conditions. Accordingly, we
propose a novel clinical-compliant protocol taking
these parameters into account to generate MiHA-
specific CD8+ T cells of optimized quality. Since no
single biomarker is sufficiently sensitive or specific on
its own to adequately determine levels of T-cell differ-
entiation and functionality, the simultaneous use of
several markers such as PD-1, KLRG-1, IFNγ and Ki67
may help to predict in vivo persistence of cultured
specific T cells. A better understanding of the mecha-
nisms by which a given antigen or a specific priming/
expansion system contribute to the induction of specific T-
cell exhaustion will be extremely valuable for the ex vivo
generation of healthy T cells for clinical applications.
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